(VIANEWS) – ESSILORLUXOTTICA (EL.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| ESSILORLUXOTTICA (EL.PA) | €174.94 | 1.83% | 6.16% |
| IBA (IBAB.BR) | €12.40 | 1.67% | 5.01% |
| SARTORIUS STED BIO (DIM.PA) | €251.00 | 0.58% | 27.04% |
| VIRBAC (VIRP.PA) | €271.00 | 0.48% | 15.51% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. ESSILORLUXOTTICA (EL.PA)
1.83% Forward Dividend Yield and 6.16% Return On Equity
EssilorLuxottica Société anonyme engages in design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses in Europe, Middle East, Africa, Latin America, Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Crizal, Essilor, Eyezen, Stellest, Xperio, Optifog, Satisloh, Barberini, Shamir, Nikon, KODAK Lens, Oakley, OPTIFOG, Ray-Ban, Transitions, Vailux, and Xperio brands. It also provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Alain Mikli, Costa del Mar, Native Eyewear, Luxottica, Sferoflex, Heritage, Sensaya, Miki Ninn, DbyD, Unofficial and Seen, Arnette, Vogue Eyewear, Bolon, Molsion, and Ossé, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of physical stores or its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ESSILORLUXOTTICA has a trailing twelve months EPS of €5.22.
PE Ratio
ESSILORLUXOTTICA has a trailing twelve months price to earnings ratio of 33.51. Meaning, the purchaser of the share is investing €33.51 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.
Moving Average
ESSILORLUXOTTICA’s value is above its 50-day moving average of €172.42 and higher than its 200-day moving average of €171.51.
Volume
Today’s last reported volume for ESSILORLUXOTTICA is 71095 which is 85.31% below its average volume of 484160.
Volatility
ESSILORLUXOTTICA’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.07%, a negative 0.07%, and a positive 1.05%.
ESSILORLUXOTTICA’s highest amplitude of average volatility was 0.81% (last week), 1.02% (last month), and 1.05% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ESSILORLUXOTTICA’s stock is considered to be overbought (>=80).
More news about ESSILORLUXOTTICA.
2. IBA (IBAB.BR)
1.67% Forward Dividend Yield and 5.01% Return On Equity
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Earnings Per Share
As for profitability, IBA has a trailing twelve months EPS of €0.2.
PE Ratio
IBA has a trailing twelve months price to earnings ratio of 62. Meaning, the purchaser of the share is investing €62 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.01%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.5%, now sitting on 361.27M for the twelve trailing months.
Volume
Today’s last reported volume for IBA is 14324 which is 14.69% below its average volume of 16791.
Yearly Top and Bottom Value
IBA’s stock is valued at €12.40 at 07:30 EST, way under its 52-week high of €19.10 and higher than its 52-week low of €11.76.
Moving Average
IBA’s worth is way below its 50-day moving average of €14.87 and way under its 200-day moving average of €15.91.
More news about IBA.
3. SARTORIUS STED BIO (DIM.PA)
0.58% Forward Dividend Yield and 27.04% Return On Equity
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €6.91.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 36.32. Meaning, the purchaser of the share is investing €36.32 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.04%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 21.6%, now sitting on 3.17B for the twelve trailing months.
Yearly Top and Bottom Value
SARTORIUS STED BIO’s stock is valued at €251.00 at 07:30 EST, way under its 52-week high of €395.80 and way above its 52-week low of €211.50.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SARTORIUS STED BIO’s EBITDA is 7.59.
More news about SARTORIUS STED BIO.
4. VIRBAC (VIRP.PA)
0.48% Forward Dividend Yield and 15.51% Return On Equity
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Earnings Per Share
As for profitability, VIRBAC has a trailing twelve months EPS of €14.34.
PE Ratio
VIRBAC has a trailing twelve months price to earnings ratio of 18.9. Meaning, the purchaser of the share is investing €18.9 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.51%.
Volatility
VIRBAC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.24%, a positive 0.06%, and a positive 1.61%.
VIRBAC’s highest amplitude of average volatility was 1.56% (last week), 1.62% (last month), and 1.61% (last quarter).
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 26, 2023, the estimated forward annual dividend rate is 1.32 and the estimated forward annual dividend yield is 0.48%.
More news about VIRBAC.
